---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014821"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:11:56.656380+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Qualigen issues $1.1M convertible debenture & enters $1.5M co-development with Marizyme for DuraGraft

## Summary
- Issued $1.1M 8% convertible debenture and warrant to Yi Hua Chen upon exercise of Alpha option for $1M cash.
- Entered co-development agreement with Marizyme to fund commercial launch of FDA-cleared DuraGraft for CABG surgery.
- Qualigen to provide up to $1.5M funding; receives share of Marizyme's gross profit on US sales capped at 2x return.
- Exclusivity period until May 31, 2024 to negotiate broader strategic relationship with Marizyme.
- DuraGraft addresses >500,000 CABG procedures annually in US; Qualigen gains participation in revenue generation.

## SEC filing metadata
- accession: 0001493152-24-014821
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000149315224014821/0001493152-24-014821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000149315224014821/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014821
- JSON: https://secwatch.observer/filing/0001493152-24-014821.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014821.txt

## Key facts
- Debt Financings
  AIxCrypto Holdings, Inc. incurred convertible notes of $1,100,000 with Yi Hua Chen at 8% per annum maturing December 31, 2024.
  - Instrument: convertible notes
  - Principal: $1,100,000
  - Counterparty: Yi Hua Chen
  - Rate: 8% per annum
  - Maturity: December 31, 2024
  - Event: incurrence
  source text: On April 12, 2024, against Chen’s Option exercise price of $1,000,000 paid to us, we delivered to Chen: - an 8% Convertible Debenture (the “Chen Debenture”) in the principal amount of $1,100,000, of like tenor as the Alpha Debenture except for the principal amount
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460702/000149315224014821/0001493152-24-014821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.